USA flag logo/image

An Official Website of the United States Government

Novel Assays for Screening the Effects of Chemical Toxicants on Cell…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43ES023530
Solicitation Year:
2013
Solicitation Topic Code:
NIEHS
Solicitation Number:
ES13-003
Small Business Information
ARUNA BIOMEDICAL, INC.
RHODES CENTER, UGA ATHENS, GA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiat
Agency: HHS
Contract: 1R43ES023530-01
Award Amount: $224,956.00
 

Abstract:

SUMMARY The overarching objective of this Phase I project is to determine the feasibility of developing both focused and broad toxicity metabolomic assays for three neural development associated windows of susceptibility (WOS) for human development. Epidemiological and laboratory studies have identified numerous chemicals suspected to be developmental neurotoxicants. These range from heavy metals that have been in our environment for millennia to newer chemicals used to limit fire damage and kill unwanted pests. New and more informative metabolomic assays will provide key pathway analysis information that when associated with adverse outcome pathways at the cellular and animal level will lead to better predictive metabolomic in vitro assays for candidate neurotoxicants. We will use our innovative and unique suite of commercialized cell type neural progenitor (hNP1TM), neuronal (hN2TM) cells and a new astrocyte line (hAstroProTM) in individual metabolomic assays. No other commercial or nonprofit organization can provide these proprietary highly enriched cells. These cells span the approximate time of neural tube formation in human development. In the second aim we will also utilize a new coculture format for neuronal (hN2TM) and glia (hAstroProTM) to be used todetermine metabolomic profiles of cell types in more complex co-culture systems. The cell to cell interaction is more representative of the cellular and tissue composition of the developing central nervous system than individual cells or co-culture systems that physically isolated populations of cells such as trans well cocultures. Specifically, we plan to use an innovative rapid label free cell separation system developed by ArunA Biomedical and collaborators after the coculture is exposed to a toxicant.This process isolates neurotoxicant exposed hN2TM and hAstroProTM cell fractions for metabolomic analysis. We believe that the selected neurotoxicants will generate WOS-specific metabolome signatures that are linked to other key events in the adverse outcomes, including cell/organ function and development, in a dose-dependent manner. This provides the foundation for developing more focused metabolomic arrays and assays that can be used with pluripotent cell derived neural cells and directly reprogrammed hNP1 cells from a diverse genetic population. This project will lead to a Phase II proposal where resulting commercial products includes an array of metabolomic assays. At the end of Phase II we will have developed neural pathway specific metabolomic assaysand global assays that use simple and complex neural developmentally relevant cell cultures. ArunA will provide this as a service (cell assays) and outsource the metabolomic analysis and in some cases lease the cell assays to specific customers. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Chemical exposures affecting human development are numerous and range from human exposures at Minamata Bay to profound neural tube defects. The advent of human stem cell technology provides a human developmental neural toxicity model and assays in which the intricacies of human neural development are reproduced and suspected neurotoxicants can be studied in a systematic fashion. We will use our three neural developmental cell stages derived from pluripotent stem cellsand a training set of compounds to develop targeted and non-targeted assays for various environmental contaminants that affect the metabolome.

Principal Investigator:

Jamie M. Chilton
706-542-4941
jchilton@arunabiomedical.com

Business Contact:

Michele Ross
706-542-9191
mross@arunabiomedical.com
Small Business Information at Submission:

ARUNA BIOMEDICAL, INC.
RHODES CENTER, UGA ATHENS, GA -

EIN/Tax ID: 155089916
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No